Li et al. reported the phase 1 trial of NB003, a potent, broad-spectrum TKI that inhibits all KIT and PDGFRA mutations in gastrointestinal stromal tumors (GIST) [52]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.